Theravance Biopharma Inc. (TBPH) Upgraded by Zacks Investment Research to “Hold”
According to Zacks, “Theravance’s sole marketed product, Vibativ, continued to perform well, with the product growing year over year. Moreover, Theravance’s efforts on the commercialization of Vibativ are encouraging. We are also positive on the company’s efforts on label expansion of the drug, which if approved for additional indications, would be commercially significant. Further, its collaboration agreement with Mylan for revefenacin, a key late-stage pipeline candidate, is a big positive. Estimates have been moving up lately ahead of the company’s third-quarter 2016 earnings release. However, the company relies heavily on Vibativ for growth, which is concerning. As a result, lower-than-expected sales of the drug would hurt the company’s top line significantly. The company expects lot of activity on the pipeline front for the rest of 2016. Any hiccup on the development front could pull down the stock significantly.”
A number of other brokerages have also weighed in on TBPH. Leerink Swann raised their target price on shares of Theravance Biopharma to $29.00 and gave the company an outperform rating in a research report on Monday, June 20th. Guggenheim assumed coverage on shares of Theravance Biopharma in a research report on Monday, June 20th. They issued a buy rating and a $30.00 target price on the stock. Bank of America Corp. lowered shares of Theravance Biopharma from a neutral rating to an underperform rating in a report on Wednesday, August 3rd. Evercore ISI assumed coverage on shares of Theravance Biopharma in a report on Monday, August 29th. They set a buy rating and a $41.00 price target on the stock. Finally, Robert W. Baird lowered shares of Theravance Biopharma from a neutral rating to an underperform rating and lifted their price target for the stock from $19.00 to $24.00 in a report on Wednesday, October 12th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $35.40.
Shares of Theravance Biopharma (NASDAQ:TBPH) traded up 4.151% on Friday, hitting $30.235. The stock had a trading volume of 162,366 shares. The firm has a 50 day moving average of $33.14 and a 200 day moving average of $25.33. Theravance Biopharma has a 12 month low of $12.87 and a 12 month high of $38.92. The stock’s market cap is $1.45 billion.
Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.01. Theravance Biopharma had a negative net margin of 471.82% and a negative return on equity of 70.79%. On average, equities analysts forecast that Theravance Biopharma will post ($4.03) earnings per share for the current fiscal year.
In related news, SVP Brett K. Haumann sold 9,509 shares of the business’s stock in a transaction on Friday, August 19th. The shares were sold at an average price of $27.97, for a total value of $265,966.73. Following the transaction, the senior vice president now owns 197,391 shares in the company, valued at $5,521,026.27. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Brett K. Haumann sold 4,491 shares of the business’s stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $27.99, for a total transaction of $125,703.09. Following the completion of the transaction, the senior vice president now owns 188,293 shares in the company, valued at approximately $5,270,321.07. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its position in Theravance Biopharma by 110.2% in the third quarter. BNP Paribas Arbitrage SA now owns 3,008 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,577 shares during the last quarter. Teacher Retirement System of Texas raised its position in Theravance Biopharma by 40.2% in the second quarter. Teacher Retirement System of Texas now owns 4,887 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 1,401 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Theravance Biopharma by 3.3% in the second quarter. PNC Financial Services Group Inc. now owns 5,992 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 192 shares during the last quarter. Paloma Partners Management Co purchased a new position in Theravance Biopharma during the second quarter valued at about $255,000. Finally, Bellevue Group AG purchased a new position in Theravance Biopharma during the first quarter valued at about $215,000. Institutional investors and hedge funds own 69.97% of the company’s stock.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.